Table 3. Results in response-adapted... | American Society of Hematology

Table 3.

Results in response-adapted studies of increased therapy in PET-positive groups

Trial name	Reference	Stage	No. of PET-positive patients	No. of cycles and type of initial therapy	% Interim PET positive	5-Point PET score (if used)	No. of cycles and type of post-PET therapy	Time to analysis (y)	PFS (%)	OS (%)
EORTC HD10	29	I-II	361	2 ABVD	19		2 ABVD + INRT	5	77	89
							2 BEACOPP_escalated + INRT		91	96
RATHL	2	II with adverse features, III, IV	182	2 ABVD	16	4-5	4 BEACOPP_escalated or 6 BEACOPP-14	3	68	87
GITIL/FIL 0607	26	II with adverse features, III, IV	98	2 ABVD	20	4-5	4 BEACOPP_escalated + 4 BEACOPP_baseline with or without rituximab	2	66	—
SWOG S0816	30	III, IV	60	2 ABVD	18	4-5	6 BEACOPP_escalated	2	64	—
FIL HD0801	31	IIB-IV	103	2 ABVD	20	3-5	4 IGEV + BEAM	2	76	—

Trial name	Reference	Stage	No. of PET-positive patients	No. of cycles and type of initial therapy	% Interim PET positive	5-Point PET score (if used)	No. of cycles and type of post-PET therapy	Time to analysis (y)	PFS (%)	OS (%)
EORTC HD10	29	I-II	361	2 ABVD	19		2 ABVD + INRT	5	77	89
							2 BEACOPP_escalated + INRT		91	96
RATHL	2	II with adverse features, III, IV	182	2 ABVD	16	4-5	4 BEACOPP_escalated or 6 BEACOPP-14	3	68	87
GITIL/FIL 0607	26	II with adverse features, III, IV	98	2 ABVD	20	4-5	4 BEACOPP_escalated + 4 BEACOPP_baseline with or without rituximab	2	66	—
SWOG S0816	30	III, IV	60	2 ABVD	18	4-5	6 BEACOPP_escalated	2	64	—
FIL HD0801	31	IIB-IV	103	2 ABVD	20	3-5	4 IGEV + BEAM	2	76	—

BEAM, carmustine, etoposide, cytarabine, and melphalan; IGEV, ifosfamide, gemcitabine, and vinorelbine.